TNFRSF1A and diabetic kidney disease: A phase II clinical trial evaluating baricitinib for DKD treatment (181) found that, after 24 weeks, baricitinib significantly reduced the morning UACR and inflammatory markers, including urinary CCL2, serum TNF-R1, TNF-R2, and ICAM levels, compared to healthy controls.